NGS library prep methods for mutation detection from cell-free DNA (ccfDNA)

The analysis of cell-free DNA (ccfDNA) derived from serum or plasma is an established method for mutational screening in cancer diagnosis, prognosis and patient stratification. Liquid biopsy NGS applications offer highly sensitive, efficient and optimized workflows.  The ccfDNA concentration in serum or plasma is normally very low, which makes sequencing library construction challenging. In this webinar, we will describe the technical challenges associated with ccfDNA sequencing and outline QIAGEN’s optimized ccfDNA workflow that combines high-efficiency NGS library construction with unbiased library amplification.

Peter Hahn, Ph.D., Associate Director R&D, NGS Technology Development

Dr. Hahn studied biology at the Saarland University, Saarbruecken, Germany and received his Ph.D. in Molecular Virology. He joined QIAGEN in 2002 spending several years working on RNAi and siRNA transfection technology and later on NGS product development. Peter is currently leading the Life Sciences NGS Technology Development focusing on product development for NGS library preparation solutions.